Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
Relative Value
There is not enough data to reliably calculate the relative value of MDGL.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Valuation Multiples
Multiples Across Competitors
MDGL Competitors Multiples
Madrigal Pharmaceuticals Inc Competitors
Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
---|---|---|---|---|---|---|---|---|
US |
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
4.8B USD | 0 | -10.8 | -8.5 | -8.5 | ||
US |
Abbvie Inc
NYSE:ABBV
|
287.1B USD | 5.3 | 48.3 | 13.5 | 20.8 | ||
US |
Amgen Inc
NASDAQ:AMGN
|
167.6B USD | 5.7 | 44.6 | 18.8 | 30.9 | ||
US |
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
113.1B USD | 11.1 | 28.1 | 23.5 | 24.6 | ||
US |
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
109B USD | 8.3 | 28.3 | 22.9 | 25.4 | ||
AU |
CSL Ltd
ASX:CSL
|
134.1B AUD | 6.3 | 36.2 | 21.9 | 27.1 | ||
US |
Gilead Sciences Inc
NASDAQ:GILD
|
83.4B USD | 3 | 172.3 | 8.7 | 11.5 | ||
US |
Moderna Inc
NASDAQ:MRNA
|
54.2B USD | 10.5 | -9.1 | -10.1 | -9 | ||
US |
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 18.8 | -57.5 | -61.9 | -55.8 | ||
US |
Biogen Inc
NASDAQ:BIIB
|
32.9B USD | 3.4 | 28.2 | 14.4 | 18 | ||
KR |
Celltrion Inc
KRX:068270
|
38.6T KRW | 17.7 | 72 | 44.1 | 60.7 |